All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...

Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...

Childhood obesity continues to be a growing problem in out country. So, should the government regulate food advertising like it did with cigarettes?

In his first confirmation hearing, Robert F. Kennedy Jr. tried to distance himself from his past statements on abortion and ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...